Management of patients with hepatitis C infection and renal disease

doi:10.4254/wjh.v7.i2.213

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9862)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

639

WORD

368

HTML

4116

Figures (1-2)

224

Tables (1-2)

194

Sum=5541

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

760

Download

1195

Sum=1955

Publishing Process of This Article

Item

Count

Browse

1198

Download

1168

Sum=2366

Feb 27, 2015 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Feb 27, 2015; 7(2): 213-225
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.213

Open in New Tab Full Size Figure Download Figure

Figure 1 Management of hepatitis C virus in patients with renal disease and kidney transplantation. Empiric dose changes should be done in conjunction with therapeutic drug monitoring. BOC: Boceprevir; TVR: Telaprevir; SMV: Simeprevir; SFV: Sofosbuvir; CYP3A4: Cytochrome P450 3A4; mTOR: Mammalian target of rapamycin; MMF: Mycophenolate mofetil.

Open in New Tab Full Size Figure Download Figure

Figure 2 Proposed pathogenesis of hepatitis C virus-related immunogenic and lymphoproliferative disorders. HCV: Hepatitis C virus; NOS: Nitric oxide synthase; ROS: Reactive oxygen species; AID: Activation-induced deaminase.

Citation: Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015; 7(2): 213-225
URL: https://www.wjgnet.com/1948-5182/full/v7/i2/213.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i2.213